Expressions Of Y-box Binding Protein-1 And Cyclin D1 In The Prostate Cancer

Objective:To detect the expression of YB-1 and D1 proteins in prostate cancer and benign prostatic hyperplasia(BPH)tissues,and to analyze their expression and age,PSA level,and clinical stage in prostate cancer and benign prostatic hyperplasia.The relationship between Gleason scores and the expression levels of YB-1 and D1 proteins in prostate tissues and their clinical significance.Methods:A total of 122 prostate cancer specimens were collected from the first affiliated hospital of Zhengzhou University from March 2013 to March 2016 and were diagnosed by pathology.The ages were 44-83 years old and the median age was 67 years.According to the preoperative PSA <20,there were 50 patients,and PSA ≥ 20 had 72 patients.According to WHO’s TNM criteria,81 patients had T1+T2 stage and 41 patients had T3+T4 stage;according to the Gleason criteria,well-differentiated cancer and moderate differentiation There were 79 cases with cancer(2-7 points)and 43 cases with poorly differentiated cancer(8-10 points).No chemotherapy or endocrine therapy was performed before surgery.Randomly selected 60 cases of benign prostatic hyperplasia tissue specimens of the same period,aged 55-84 years old,with a median age of 69 years.All tissues were confirmed by histopathology.Immunohistochemistry was used to detect the expression of YB-1 and D1 proteins in the tissues.SPSS 21.0 statistical software was used for statistical analysis of the data,with P < 0.05 as the difference was statistically significant.Results:1.In 122 cases of prostate cancer,the positive rate of YB-1 in prostate cancer was 74.6%(91/122).The positive rate of YB-1 in benign prostatic hyperplasia was 15%(9/60).The difference was statistically significant(P<0.05).The expression of YB-1 was not related to age.The positive expression rates in the two groups were 70%(≥70 years old)and 76.8%(<70 years old),respectively,with no statistically significant difference(P < 0.05);with preoperative PSA The level of elevation increased and the positive rate in the two groups was 81.9%(PSA≥20)and 64%(PSA<20),respectively.The difference was statistically significant(P<0.05).It increased with the increase of clinical pathological staging.The group was 87.8%(clinical stage ≥T3),67.9%(clinical stage<T3),the difference was statistically significant(P<0.05),and increased with the decrease of the Gleason criteria,and the expression rate was 88.3%(Gleason score ≥ 8),67.1%(Gleason score <8),the difference was statistically significant(P <0.05).2.In 122 cases of prostate cancer,the positive rate of D1 in prostate cancer was 69.7%(85/122),and in 60 cases of benign prostatic hyperplasia(16.7%(10/60)).Significance(P<0.05).The expression of D1 was not related to age.The positive expression rates in the two groups were 67.5%(≥70 years old)and 70.7%(<70 years old,respectively),with no statistically significant difference(P < 0.05).The preoperative PSA level increased.However,the positive rate in the two groups was 80.6%(PSA≥20)and 54%(PSA<20),respectively.The difference was statistically significant(P<0.05).It increased with the increase of clinical pathological staging.The two groups were 85.4%(clinical stage ≥ T3),61.7%(clinical stage < T3),the difference was statistically significant(P <0.05);with the Gleason score decreased,the expression rate was 86%(Gleason score ≥ 8),60.8%(Gleason score <8),the difference was statistically significant(P <0.05).3.In prostate cancer tissues,YB-1 and D1 co-expressed positively in 76 cases and negative in 25 cases.Their expression was positively correlated(r=0.459,P<0.05).Conclusions:1.There are significant differences in the expression of cyclin D1 and YB-1 in prostate cancer tissues and benign prostatic hyperplasia tissues,suggesting that they may become new tumor markers for prostate cancer.2.There were significant differences in the expression of cyclin D1 in different clinical stages,Gleason scores and PSA levels in prostate cancer.The expression of cyclin D1 and YB-1 was positively correlated in prostate cancer tissues,indicating that both of them are in prostate cancer.There may be synergies in the development.